On July 29, 2011, the Federal Circuit upheld the validity of the patents covering Finnegan client Eli Lilly and Company’s attention deficit hyperactivity disorder treatment, Strattera®. The Federal Circuit found the patent is valid and enforceable until it expires in May 2017, finding that a U.S. Patent and Trademark Office rule that regulates patent submission had been misinterpreted by the lower court. Generic-drug makers Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA Inc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., Actavis, and Apotex had hoped to invalidate the patent in order to market generic versions of Lilly’s blockbuster drug. Finnegan represented Lilly in this matter.
Media Mention
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Commentary
April 11, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.